Mckesson CORP: directors' dealings · United States · SEC (Form 4)

About Mckesson CORP

McKesson Corp. (NYSE: MCK) is one of the largest healthcare supply-chain and services companies in the United States, with a business model centered on pharmaceutical distribution, prescription technology solutions, and higher-value specialty healthcare services. Headquartered in Irving, Texas, United States, McKesson sits at a critical point in the healthcare ecosystem, serving pharmacies, hospitals, physician practices, manufacturers, payers, and government-related customers. Founded in 1833, the company has a long operating history and has evolved from a traditional wholesaler into a diversified healthcare infrastructure provider. McKesson’s core franchise remains large-scale pharmaceutical distribution. The company distributes branded, generic, specialty, biosimilar, and over-the-counter drugs in the U.S. and Canada, while also supplying medical-surgical products and related healthcare goods. Beyond distribution, McKesson offers services designed to improve medication access, affordability, transparency, and adherence. Its capabilities extend into oncology and multispecialty care, which management has highlighted as a strategic growth area due to their higher-margin profile and stronger differentiation versus commodity distribution. The company now reports through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This structure better reflects McKesson’s evolving mix and emphasizes the company’s push toward more focused capital allocation and clearer strategic reporting. The Prescription Technology Solutions platform connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma clients, supporting prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support. In practical terms, McKesson operates as both a logistics powerhouse and a healthcare services enabler. Competitive positioning is strong because McKesson operates at scale in an industry where distribution density, service reliability, regulatory execution, and customer relationships are essential. The company says it offers more than 285,000 national brand products, alongside its own private-label offerings, through its U.S. distribution network. It also maintains a broad geographic footprint across North America, with distribution centers, pharmacy locations, and business offices in the United States and internationally. Recent developments have been important for investors. In 2025, McKesson announced a new organizational structure and disclosed its intent to separate the Medical-Surgical Solutions segment. It also moved ahead with the sale of its Norway businesses. More recently, fiscal 2026 results showed continued revenue growth and strong adjusted earnings expansion, supported by specialty product distribution and disciplined execution. For investors on the NYSE, McKesson remains a high-quality U.S. healthcare platform with defensive cash generation and selective growth exposure in specialty care and prescription technology.